KRKristen K. Renneker

Kristen K. Renneker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristen K. Renneker has a total of 354 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Defining ocular Chlamydia trachomatis infection prevalence thresholds for the trachoma elimination endgame

    by Anna Borlase, Jacob A Cohen, Everlyn Kamau, Rosemary Pearson-Clarke, Kristen K Renneker, Fentahun Tadesse Akale, Paul Akampurira, Abdou Amza, Sue Chen Apadinuwe, Solomon Aragie, et al.

    Trachoma is the leading infectious cause of blindness worldwide and is targeted for global elimination as a public health problem by 2030. As we approach this target, defining when population-level trachoma control interventions can be stopped, and determining how post-intervention surveillance should be performed, are becoming increasingly important. Molecular diagnosis of ocular Chlamydia trachomatis (Ct) using polymerase chain reaction (PCR) provides a highly sensitive and specific indicator of infection, yet there are currently no programmatic guidelines based on Ct infection. We assembled 86 cross-sectional surveys of ocular Ct infection from 13 countries, representing data from 46,914 children aged 1-5 years. Our analyses suggest that infection prevalence of 0.81% in this age group corresponds to a threshold below which population-level interventions can be stopped with at least 90% confidence. Correspondingly, with confidence exceeding 90%, we propose that interventions should continue when infection prevalence is greater than 1.99%. Interpretation of infection surveillance data is a generalisable challenge in low-prevalence settings for many infectious diseases. This study proposes a robust framework for how Ct infection surveillance could support accurate population-level assessments of trachoma endemicity and could allow a step-change in decision-making precision for programmes as we approach the endgame for trachoma elimination.

  • Open Access

    Correlates of trachoma persistence and recrudescence: A global analysis of 33 countries

    by Kristen K. Renneker, Scott D. Nash, N’DEye Marie A. Bassabi-Alladji, Victor Bucumi, Andre Eballe Omgbwa, Julian Trujillo Trujillo, N’GOran Norbert Dje, Naomi Pitchouna Uvon, Tesfahun Bishaw, Adisu Abebe, et al.

  • Open Access

    Comparison of methods for assessing Chlamydia trachomatis transmission intensity: a systematic review

    by Kristen K Renneker, Che-Chi Lin, Jennifer L Hsieh, Pj Hooper, Robert Butcher, T Déirdre Hollingsworth, Diana L Martin, Anthony W Solomon, Emma M Harding-Esch

    Structured Topic: To assess the relationship between field-graded trachomatous inflammation—follicular (TF) and other methodologies for evaluating Chlamydia trachomatis ( Ct) transmission intensity. Clinical relevance: TF has limitations as the sole indicator of Ct transmission for trachoma programmatic decision-making. The relationships between TF and other indicators, including other clinical signs, photography, infection, and serology have yet to be synthesized. Methods: A systematic review was conducted. Five databases (MEDLINE, EMBASE, Global Health database, Scopus, and Global Index Medicus) were searched on October 19, 2022, and the e-Theses Online Service was searched on April 12, 2023. Studies from 1987 onward that reported primary data collection of field-graded TF in children and at least one other indicator were included. To compare field-graded vs. photo-graded TF, the mean difference in prevalence and 95% confidence intervals (CIs) were calculated. To compare field-graded TF against the other indicators, weighted correlation coefficients and p-values were calculated in pre-vs. post-antibiotic mass drug administration (MDA) settings. The review protocol was prospectively registered with PROSPERO (CRD42022356013). Results: A total of 35,764 studies were screened, yielding 235 included studies from 49 countries, spanning the years (of data collection) 1991–2021. For field-graded vs. photo-graded TF (n=10), the mean difference in prevalence was 0.7 percentage points, 95% CI (−15.2–16.7). The relationship between TF and other indicators was stronger pre-vs. post-MDA: TF vs infection (R 2 : 0.43, p=0.003 vs. R 2 : 0.002, p=0.788); TF vs seroprevalence (R 2 : 0.56, p2 : 0.03, p=0.353); and TF vs seroconversion rate (SCR) (R 2 : 0.52, p=0.012 vs. R 2 : 0.26, p=0.061). Post-MDA, infection and SCR were highly correlated (R 2 : 0.71, p=0.001). In studies reporting data used for programmatic decision-making, 48% of the areas warranting MDA based solely on TF had at least one other indicator categorized as indicating “low” or “medium” Ct transmission intensity. Conclusions: The correlation between TF and measures of infection and serology weakens post-initiation of MDA, which is strongly suggestive of poor performance of TF prevalence for guiding programmatic decision-making post-MDA. Measures of infection and SCR are strongly correlated with each other post-MDA. Infection and/or serology should be considered to help guide programmatic decision-making post-MDA. Target Journal: Ophthalmology


  • Open Access

    Characterizing trachoma elimination using serology

    by Everlyn Kamau, Pearl Anne Ante-Testard, Sarah Gwyn, Seth Blumberg, Zeinab Abdalla, Kristen Aiemjoy, Abdou Amza, Solomon Aragie, Ahmed M. Arzika, Marcel S. Awoussi, et al.

    Trachoma is targeted for global elimination as a public health problem by 2030. Measurement of IgG antibodies in children is being considered for surveillance and programmatic decision-making. There are currently no programmatic guidelines based on serology, which represents a generalizable problem in seroepidemiology and disease elimination. Here, we collate Chlamydia trachomatis Pgp3 and CT694 IgG measurements from 48 serosurveys across Africa, Latin America, and the Pacific Islands (41,168 children ages 1–5 years) and propose a novel approach to estimate the probability that population C. trachomatis transmission is below or above levels requiring ongoing programmatic action. We determine that trachoma programs could halt control measures with >90% certainty when seroconversion rates (SCRs) are ≤2.2 per 100 person-years. Conversely, SCRs ≥4.5 per 100 person-years correspond with >90% certainty that further control interventions are needed. More extreme SCR thresholds correspond with higher levels of confidence of elimination (lower SCR) or ongoing action needed (higher SCR). This study demonstrates a robust approach for using trachoma serosurveys to guide elimination program decisions.


  • Open Access

    Acceptability and feasibility of tests for infection, serological testing, and photography to define need for interventions against trachoma

    by Kristen K. Renneker, Tara B. Mtuy, George Kabona, Stephen Gabriel Mbwambo, Patrick Mosha, Jeremiah Mepukori Mollel, Pj Hooper, Paul M. Emerson, T. Deirdre Hollingsworth, Robert Butcher, et al.

    Background: Trachoma causes blindness due to repeated conjunctival infection by Chlamydia trachomatis (Ct). Transmission intensity is estimated, for programmatic decision-making, by prevalence of the clinical sign trachomatous inflammation—follicular (TF) in children aged 1–9 years. Research into complementary indicators to field-graded TF includes work on conjunctival photography, tests for ocular Ct infection, and serology. The perceived acceptability and feasibility of these indicators among a variety of stakeholders is unknown. Methodology: Focus group discussions (FGDs) with community members and in-depth interviews (IDIs) with public health practitioners in Tanzania were conducted. FGDs explored themes including participants’ experience with, and thoughts about, different diagnostic approaches. The framework method for content analysis was used. IDIs yielded lists of perceived strengths of, and barriers to, implementation for programmatic use of each indicator. These were used to form an online quantitative survey on complementary indicators distributed to global stakeholders via meetings, mailing lists, and social media posts. Results: Sixteen FGDs and 11 IDIs were conducted in October–November 2022. In general, all proposed sample methods were deemed acceptable by community members. Common themes included not wanting undue discomfort and a preference for tests perceived as accurate. Health workers noted the importance of community education for some sample types. The online survey was conducted in April–May 2023 with 98 starting the questionnaire and 81 completing it. Regarding barriers to implementing diagnostics, the highest agreement items related to feasibility, rather than acceptability. No evidence of significant differences was found in responses pertaining to community acceptability based on participant characteristics. Conclusions: All of the indicators included were generally deemed acceptable by all stakeholders in Tanzania, although community education around the benefits and risks of different sample types, as well as addressing issues around feasibility, will be key to successful, sustainable integration of these indicators into trachoma programs.


  • Open Access

    Acceptability and feasibility of tests for infection, serological testing and photography to define need for interventions against trachoma

    by Kristen K Renneker, Tara B Mtuy, George Kabona, Stephen Gabriel Mbwambo, Patrick Mosha, Jeremiah Mepukori Mollel, Pj Hooper, Paul M Emerson, T. Deirdre Hollingsworth, Robert Butcher, et al.

    Background: Trachoma causes blindness due to repeated conjunctival infection by Chlamydia trachomatis ( Ct ). Transmission intensity is estimated, for programmatic decision-making, by prevalence of the clinical sign trachomatous inflammation—follicular (TF) in children aged 1–9 years. Research into complementary indicators to field-graded TF includes work on conjunctival photography, tests for ocular Ct infection, and serology. The perceived acceptability and feasibility of these indicators among a variety of stakeholders is unknown. Methodology: Focus group discussions (FGDs) with community members and in-depth interviews (IDIs) with public health practitioners in Tanzania were conducted. FGDs explored themes including participants’ experience with, and thoughts about, different diagnostic approaches. The framework method for content analysis was used. IDIs yielded lists of perceived strengths of, and barriers to, implementation for programmatic use of each indicator. These were used to form an online quantitative survey on complementary indicators distributed to global stakeholders via meetings, mailing lists, and social media posts. Results: Sixteen FGDs and 11 IDIs were conducted in October–November 2022. In general, all proposed sample methods were deemed acceptable by community members. Common themes included not wanting undue discomfort and a preference for tests perceived as accurate. Health workers noted the importance of community education for some sample types. The online survey was conducted in April–May 2023 with 98 starting the questionnaire and 81 completing it. Regarding barriers to implementing diagnostics, the highest agreement items related to feasibility, rather than acceptability. No evidence of significant differences was found in responses pertaining to community acceptability based on participant characteristics. Conclusions: All of the indicators included were generally deemed acceptable by all stakeholders in Tanzania, although community education around the benefits and risks of different sample types, as well as addressing issues around feasibility, will be key to successful, sustainable integration of these indicators into trachoma programs. Author Summary: Trachoma is a disease that causes blindness through conjunctival infection with the bacterium Chlamydia trachomatis . Trachoma is targeted for global elimination by 2030. To know whether population-level interventions are required, we must know how intensely conjunctival C. trachomatis is being transmitted in a population. The current proxy recommended by the World Health Organization is prevalence of a clinical sign of active (inflammatory) trachoma: trachomatous inflammation—follicular. However, this indicator has several drawbacks. Policy-makers are considering the utility of a number of complementary indicators, including conjunctival photography and tests for infection and serology. We sought the opinions of different stakeholders to determine the acceptability and feasibility of complementary indicators for use in trachoma programs. In Tanzania, we undertook focus group discussions with community members and in-depth interviews with public health practitioners. We also conducted an online survey of global stakeholders. We found that all the proposed test types were acceptable to stakeholders in Tanzania; common themes included not wanting undue discomfort and a preference for test types perceived to be accurate. Community education and building trust was deemed critical. From the online survey, the most agreed-upon barriers to implementation of each method were related to concerns about feasibility, rather than acceptability.


  • Open Access

    Tropical Data: Approach and Methodology as Applied to Trachoma Prevalence Surveys

    by Emma M Harding-Esch, Clara R Burgert-Brucker, Cristina Jimenez, Ana Bakhtiari, Rebecca Willis, Michael Dejene Bejiga, Caleb Mpyet, Jeremiah Ngondi, Sarah Boyd, Mariamo Abdala, et al.

    Population-based prevalence surveys are essential for decision-making on interventions to achieve trachoma elimination as a public health problem. This paper outlines the methodologies of Tropical Data, which supports work to undertake those surveys. Tropical Data is a consortium of partners that supports health ministries worldwide to conduct globally standardised prevalence surveys that conform to World Health Organization recommendations. Founding principles are health ministry ownership, partnership and collaboration, and quality assurance and quality control at every step of the survey process. Support covers survey planning, survey design, training, electronic data collection and fieldwork, and data management, analysis and dissemination. Methods are adapted to meet local context and needs. Customisations, operational research and integration of other diseases into routine trachoma surveys have also been supported. Between 29th February 2016 and 24th April 2023, 3373 trachoma surveys across 50 countries have been supported, resulting in 10,818,502 people being examined for trachoma. This health ministry-led, standardised approach, with support from the start to the end of the survey process, has helped all trachoma elimination stakeholders to know where interventions are needed, where interventions can be stopped, and when elimination as a public health problem has been achieved. Flexibility to meet specific country contexts, adaptation to changes in global guidance and adjustments in response to user feedback have facilitated innovation in evidence-based methodologies, and supported health ministries to strive for global disease control targets.


  • Open Access

    Forecasting the elimination of active trachoma: An empirical model

    by Kristen K. Renneker, Paul M. Emerson, P. J. Hooper, Jeremiah M. Ngondi

    Background: Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when the program will attain the goal of the elimination of active trachoma, defined as prevalence of trachomatous inflammation—follicular in 1–9 year olds (TF1–9) 1–9.Methodology/Principal findings: We calculated the mean number of years (95% CI) observed for an implementation unit (IU) to move from a baseline TF1–9prevalence ≥5% to the elimination threshold, based on the region (Ethiopia vs. non-Ethiopia) and baseline prevalence category. Ethiopia IUs had significantly different rates of reaching the TF1–9elimination threshold after a trachoma impact survey (TIS) compared to non-Ethiopia IUs across all baseline categories. We used those estimates to predict when remaining active trachoma-endemic IUs (TF1–9≥5%) would have their last round of mass drug administration (MDA) based on the mean number of years required and number of MDA rounds already completed. Our model predicts that elimination of TF1–9will be achieved in 2028 in Ethiopia (95% CI: 2026–2033) and 2029 outside of Ethiopia (95% CI: 2023–2034), with some IUs in East Africa predicted to be the last requiring MDA globally.Conclusions/Significance: Our empirical estimate is similar to those resulting from previous susceptible-infectious-susceptible (SIS) and mathematical models, suggesting that the forecast achievement of TF1–9elimination is realistic with the caveat that although disease elimination progress can be predicted for most IUs, there is an important minority of IUs that is not declining or has not yet started trachoma elimination activities. These IUs represent an important barrier to the timely global elimination of active trachoma.


  • Open Access

    Global progress toward the elimination of active trachoma: an analysis of 38 countries

    by Kristen K Renneker, Mariamo Abdala, James Addy, Tawfik Al-Khatib, Khaled Amer, Mouctar Dieng Badiane, Wilfrid Batcho, Lucienne Bella, Clarisse Bougouma, Victor Bucumi, et al.


  • Open Access

    The Importance of Failure: How Doing Impact Surveys That Fail Saves Trachoma Programs Money

    by Anthony W. Solomon, Pamela J. Hooper, Mathieu Bangert, Upendo J. Mwingira, Ana Bakhtiari, Molly A. Brady, Christopher Fitzpatrick, Iain Jones, George Kabona, Amir B. Kello, et al.

    Trachoma programs use annual antibiotic mass drug administration (MDA) in evaluation units (EUs) that generally encompass 100,000–250,000 people. After one, three, or five MDA rounds, programs undertake impact surveys. Where impact survey prevalence of trachomatous inflammation—follicular (TF) in 1- to 9-year-olds is ≥ 5%, ≥ 1 additional MDA rounds are recommended before resurvey. Impact survey costs, and the proportion of impact surveys returning TF prevalence ≥ 5% (the failure rate or, less pejoratively, the MDA continuation rate), therefore influence the cost of eliminating trachoma. We modeled, for illustrative EU sizes, the financial cost of undertaking MDA with and without conducting impact surveys. As an example, we retrospectively assessed how conducting impact surveys affected costs in the United Republic of Tanzania for 2017–2018. For EUs containing 100,000 people, the median (interquartile range) cost of continuing MDA without doing impact surveys is USD 28,957 (17,581–36,197) per EU per year, whereas continuing MDA solely where indicated by impact survey results costs USD 17,564 (12,158–21,694). If the mean EU population is 100,000, then continuing MDA without impact surveys becomes advantageous in financial cost terms only when the continuation rate exceeds 71%. For the United Republic of Tanzania in 2017–2018, doing impact surveys saved enough money to provide MDA for > 1,000,000 people. Although trachoma impact surveys have a nontrivial cost, they generally save money, providing EUs have > 50,000 inhabitants, the continuation rate is not excessive, and they generate reliable data. If all EUs pass their impact surveys, then we have waited too long to do them.